Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

G7 leaders agreed in June to engineer a $50 billion loan to help Ukraine in its fight for survival. Interest earned on ...

Stock futures edged lower as the dust settled after Thursday's rally, and bond yields traded just shy of two week highs. Investors will see option contracts tied to more than $5 trillion in tradeable ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Novo Nordisk said it expects the European Medicines Agency to implement the EU label update on Wegovy to reflect reduced heart failure symptoms and improved physical function shortly. The company also ...

BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Compounding pharmacies that offer their own homebrew GLP-1 drugs are the new designer smoke shops: Illegal, unsafe, and ...

The Northeast Microelectronics Coalition Hub announced on Wednesday that it had been awarded $37.8 million in federal ...

Drew, a 36-year-old man from San Antonio, Texas, drove more than 250 miles to Mexico to buy cheap Ozempic to help him lose ...